Lexaria’s Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly’s Injectable GLP-1/GIP Drug Zepbound® lexariabioscience.com/2025/01/14/lex… $LEXX #weightloss #weightlossmeds #glp1 #loseweight #diabetes #jpm25 #jpm2025 #obesity

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval - First-ever human investigation for DehydraTECH-liraglutide in an oral capsule format lexariabioscience.com/2025/01/15/lex… $LEXX #trading #weightloss #glp1 #loseweight #diabetes #jpm25 #jpm2025 #obesity

Lexaria Updates its Ongoing Human Study GLP-1-H24-4 Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss lexariabioscience.com/2025/02/05/lex… $LEXX #weightloss #glp1 #loseweight #diabetes #stocks #stockmarket #investing

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway World’s First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules lexariabioscience.com/2025/02/06/lex… $LEXX #weightloss #glp1 #loseweight #diabetes #stocks #stockmarket #investing #stockmarketnews #trading

.Lexaria Bioscience's oral delivery technology reduces side effects by 50% for a top diabetes drug—while maintaining powerful results! Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Learn more: lexariabioscience.com/2025/01/14/lex… $LEXX

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy - Additions broaden DehydraTECH patent suite for #Epilepsy $LEXX #Biotech #nasdaq #DrugDelivery #CBD #markets #stocks #stockmarket #investing #stockmarketnews #trading

Lexaria’s Strategic Business Pursuit of DehydraTECH-Liraglutide - Pursuing the world’s first-ever orally-dosed #liraglutide lexariabioscience.com/2025/02/20/lex… $LEXX #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #loseweight #diabetes

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm lexariabioscience.com/2025/02/24/eth… $LEXX #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #weightlossmeds #weightlossmedications #weightlossmanagement #glp1 #loseweight #diabetes

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience lexariabioscience.com/2025/02/27/the… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #loseweight #diabetes

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience lexariabioscience.com/2025/02/27/the… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #loseweight #diabetes

Be Part of the New Biotech Revolution | Lexaria Bioscience Imagine a world where weight loss & diabetes treatments no longer require injections. 🌍💡 Lexaria Bioscience ( $LEXX ) is revolutionizing drug delivery with DehydraTECH™, a patented oral technology designed to enhance

$LEXX BREAKTHROUGH ALERT: Lexaria Bioscience’s oral DehydraTECH™-tirzepatide achieves comparable levels in bloodstream to injectable Zepbound®—with 47% fewer side effects! 💊⚡ A major breakthrough in diabetes & weight loss treatment. Learn more: morningstar.com/news/accesswir… #Biotech

Lexaria’s DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound® lexariabioscience.com/2025/03/18/lex… $LEXX #Biotech #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #glp1 #loseweight #diabetes

Lexaria’s Human GLP-1 Study #5 Begins Dosing - Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide lexariabioscience.com/2025/04/02/lex… $LEXX #markets #stocks #stockmarket #investing #trading #weightloss #glp1 #diabetes

Lexaria Updates its Ongoing Human Study GLP-1-H24-4 - Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss lexariabioscience.com/2025/04/03/lex… $LEXX #Biotech #DrugDelivery #markets #stocks #stockmarket #investing #trading #weightloss #glp1 #diabetes

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology lexariabioscience.com/2025/04/23/rec… $LEXX #Biotech #DrugDelivery #markets #stocks #stockmarket #investing #trading #weightloss #glp1 #diabetes

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company lexariabioscience.com/2025/05/12/lex… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading

Lexaria Attending BIO International Convention - Biotechnology Sector’s Premier Strategic Partnering Event lexariabioscience.com/2025/06/05/lex… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria’s DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule lexariabioscience.com/2025/06/11/lex… $LEXX #Biotech #markets #stocks #stockmarket #investing #stockmarketnews #trading #weightloss #glp1 #diabetes

Lexaria Reaches Patent Milestone – 50 Patents Now Granted Worldwide!! lexariabioscience.com/2025/06/23/lex… $LEXX #Biotech #nasdaq #DrugDelivery #markets #stocks #stockmarket #investing #stockmarketnews #trading #patent